| Nov 14 |
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know
|
| Nov 7 |
Lyell Immunopharma: Q3 Earnings Snapshot
|
| Nov 7 |
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
|
| Nov 5 |
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
|
| Nov 1 |
LiveOne Leads The Pack Of 3 US Penny Stocks
|
| Oct 31 |
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
|
| Oct 30 |
Lyell shares down as BofA double downgrades to Sell
|
| Oct 30 |
Lyell cut to underperform by BofA, pipeline reorganization cited
|
| Oct 25 |
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
|
| Oct 25 |
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth
|
